Regulatory
FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, provides a trading update for the six month period ended 30 June 2019.
Double-digit sales growth delivered by Pharma Biotech & Nutrition (LPBN) segment
Expansion to bioconjugation facility in Visp, Switzerland to meet increasing clinical, launch and commercial market demand
As 2019 enters its second half, BioSpace takes a look at some of the warning letters issued by the U.S. Food and Drug Administration to the biopharma industry.
Retrophin, Inc. announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, announced that it will host a conference call on Thursday, August 1, 2019 at 5pm ET to discuss second quarter 2019 financial results and provide a corporate update.
For LENVIMA plus KEYTRUDA Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
Low cost production and superior product purity of the diabetes drug liraglutide with NUMAFERM’s unique technology platform
Recipharm AB will publish its interim report for January - June 2019 on 25th July at 07:45 am CET.
PRESS RELEASES